SecBot SecBot
8-K ·Filed Nov 3, 2026

MIRM

Mirum Pharmaceuticals, Inc.
BULLISH
Impact 6/10
Horizonmonths Processed13d 9h ago SEC0001759425-26-000061
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

Watch for upcoming catalysts: brelovitug AZURE-4 data in Q4 2026, volixibat VANTAGE data in Q1 2027, and multiple regulatory submissions planned for H1 2027. The raised guidance and new product launch (ATEBRIOZ) provide near-term revenue visibility.

DirectionBullish
Confidencehigh
Horizonmonths

Drugs in focus

MIRM drug pipeline →

brelovitug

▲ Bullish Named in this 8-K
Impact
Phase
Phase 3 (completed)
Time to market
Mirum plans to submit a Biologics License Application (BLA) to the FDA in the first half of 2027, supported by the positive AZURE-1 and AZURE-4 results. If accepted and approved, commercial launch could follow in late 2027 or early 2027.
Next catalyst
BLA filing · H1 2027

What to watchBrelovitug has cleared its two pivotal Phase 3 trials (AZURE-1 and AZURE-4), setting up a BLA submission in H1 2027. The stock already reflects significant optimism (analyst mean target $155 vs ~$94 close), and the next major binary event is the BLA acceptance and subsequent FDA review. Watch for the AZURE-2 head-to-head data against Gilead's Hepcludex, which will determine brelovitug's commercial positioning in a market with one existing approved therapy.

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+5
Entry
$96.97
T+0 close · Nov 3, 2026 · via day close
Latest settled
−2.43%
T+5 · $94.61 · next T+20 in 16d
Vs SPY
−1.52%
α at T+5
Latest observation
−2.52%
T+7 · FF3 residual α
  1. T+0 · Nov 4 $96.97entry
  2. T+1 · 12d ago −3.54%α +0.87% · $93.54
  3. T+5 · 6d ago −2.43%α −1.52% · $94.61
  4. T+8 · todayOpen
  5. T+20 · in 16d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Mirum Pharmaceuticals reported Q3 2026 net product sales of $185.7M, up 39.6% YoY, and raised full-year guidance to $715M-$720M. The company received FDA approval for ATEBRIOZ (zilurgisertib) in FOP and reported positive Phase 3 results for LIVMARLI and brelovitug. GAAP net loss was $40.8M ($0.62 per basic share), versus net income of $2.9M in Q3 2025.

Key Financial Metrics

EPS
−$0.62
Revenue
$185.7M
est $178.0M · +4.3% · +39.6% YoY
Guidance
$715M-$720M
raised

Key Facts

  • Q3 2026 net product sales $185.7M vs $133.0M YoY (+39.6%)
  • 2026 net product sales guidance raised to $715M-$720M from $680M-$700M
  • LIVMARLI sales $133.4M (+45% YoY); Bile Acid Medicines $52.3M (+28% YoY)
  • FDA approved and launched ATEBRIOZ (zilurgisertib) for FOP
  • LIVMARLI EXPAND Phase 3 met primary endpoint with statistical significance
  • Brelovitug AZURE-1 Phase 3 in HDV met primary endpoint
  • GAAP net loss $40.8M vs net income $2.9M in Q3 2025
  • Cash and investments $500.5M as of Sep 30, 2026
  • Repurchased $20M of convertible notes due 2029

Financial Impact

Q3 revenue beat consensus of $178.0M by $7.7M (+4.3%); full-year guidance raised by $15M-$20M at midpoint

revenueguidance

Segment Breakdown

SegmentRevenueGrowth
LIVMARLI$133.4M+45.0%
Bile Acid Medicines$52.3M+28.0%

Risk Factors

  • Company remains GAAP net loss-making with operating expenses growing faster than revenue
  • Pipeline setbacks (volixibat NDA delay, brelovitug AZURE-4 results) could reset expectations
  • Stockholders' deficit of $54.2M as of Sep 30, 2026 indicates accumulated losses

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001759425-26-000061
Document: mirm-20261103.htm0001759425-26-000061
Document: 0001759425-26-000061-index-headers.html0001759425-26-000061
Document: 0001759425-26-000061-index.html0001759425-26-000061
Document: 0001759425-26-000061.txt0001759425-26-000061
8-K Data (Synthetic)0001759425-26-000061

Track record

27 reports on MIRM

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +28.29% at T+20 after the Jun 11, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $92.28 Now $91.58 −0.76% settles Feb 12
  2. Nov 13, 20263d ago Insider Cluster Neutral 3/10 Entry $93.54 Now $91.58 −2.10% settles Feb 12
  3. Nov 12, 20264d ago 144 Neutral 2/10 Entry $93.33 Now $91.58 −1.88% settles Feb 10
  4. Nov 10, 20266d ago 8-K Bullish 6/10 Entry $94.42 Now $91.58 −3.01% settles Feb 8
  5. Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
  6. Nov 4, 202612d ago 144 Neutral 2/10 Entry $93.54 Now $91.58 −2.10% settles Feb 3
  7. Nov 3, 202613d ago 8-K Bullish 6/10 Viewing Entry $96.97 Now $91.58 −5.56% settles Feb 2
  8. Oct 27, 202620d ago Institutional Cluster Mixed 4/10 Entry $85.81 Now $91.58 +6.72% settles Jan 26
  9. Oct 26, 202621d ago 8-K Bullish 6/10 Entry $85.56 Now $91.58 +7.04% settles Jan 25
  10. Oct 13, 20264w ago 8-K Bullish 7/10 Entry $79.62 Now $91.58 +15.02% settles Jan 8
Showing 10 of 27

US Market Status

Market Closed · Opens in 7h 47m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 3, 2026